Iclusig (ponatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUM	MBER:				
MALE FEMALE HEIG	GHT (IN/CM): WEIGH	IT (LB/KG): ALLERGI	ES:		
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP					
DATIENT'S ALITHORIZED REDE	PESENITATIVE (IE ADDI ICARI E).				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:					
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL I	DISDENSING INFORMATION				
MEDICATION ON MEDICAL DISPENSING INFORMATION MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:		
		THERAPY/REFILLS:			
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):				

Continued on next page



Iclusig (ponatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Chronic Myeloid Leukemia(CML)		
□ Acute Lymphoblastic Leukemia(ALL)		
☐ Other diagnosis:ICE	0-10	
3 REQUIRED CLINICAL INFORMATION	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.	V. I LLASE I NOVIDE ALE NELEVANT CLINN	CALINI ONIVIATION TO SOTT ON TA
Clinical Information:		
	atient as part of a treatment regimen sp	pecified within a sponsored clinical
trial? 🗆 Yes 🗆 No		·
Has patient had a previous trial of Gl	eevec(imatinib)? 🗆 Yes 🗆 No <i>Please pi</i>	ovide dates of treatment.
Has patient had a previous trial of Sp	rycel(dasatinib)? Yes No Please pr	ovide dates of treatment.
Has patient had a previous trial of Ta	signa(nilotinib)? □ Yes □ No <i>Please pro</i>	ovide dates of treatment.
		•
Has patient had a previous trial of Bo	sulif(bosutinib)? 🗆 Yes 🗆 No <i>Please pr</i>	ovide dates of treatment.
Does patient have Philadelphia chror	nosome positive ALL(Ph+ALL)? □ Yes □	No Please submit chart
documentation.	,	
	-positive CML (chronic phase, accelerate	• •
mutation.	e submit a tumor genetics analysis repo	rt documenting the presence of a T315I
Are there any other comments diagram	acces symptoms modications tried or f	ailed, and/or any other information the
physician feels is important to this re		alled, and/or any other information the
projection to the projection to this re-		
	re covered on all plans. This request may	y be denied unless all required
information is received.		



Iclusig (ponatinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

NACRADED'S FIDST NIABAE.

IVIEIVIDER 3 LAST INAIVIE:	IVIEIVIDER 3 FIR31 INAIVIE:			
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that				
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this form.				
information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If				
you are not the intended recipient, you are hereby notified that any disclo	sure, copying, distribution, or action taken in reliance on the contents			
of these documents is strictly prohibited. If you have received this information	ation in error, please notify the sender immediately (via return FAX)			
and arrange for the return or destruction of these documents.				

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



NACNADED'S LAST NIABAE.